NYSEAMERICAN:CLDI

Calidi Biotherapeutics Q3 2025 Earnings Results & Report

Calidi Biotherapeutics logo
$0.60 -0.02 (-3.15%)
Closing price 11/16/2026 04:10 PM Eastern
Extended Trading
$0.61 +0.01 (+1.11%)
As of 11/16/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Calidi Biotherapeutics reported Q3 2025 earnings on November 13, 2025. The company reported EPS of -$35.36.

Earnings Announcement Details

Quarter
Q3 2025
Time
After Market Closes

Calidi Biotherapeutics EPS Results

Actual EPS
-$35.36
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Calidi Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Calidi Biotherapeutics Q3 2025 Earnings FAQ

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) reported earnings of -$35.36 per share for Q3 2025. The report was announced on Thursday, November 13, 2025.

Calidi Biotherapeutics Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Calidi Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Calidi Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Calidi Biotherapeutics and other key companies, straight to your email.

About Calidi Biotherapeutics

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) is a clinical-stage biotechnology company developing cell-based therapies for cancer. Its approach uses stem cells as delivery vehicles for oncolytic viruses, which are designed to infect and destroy cancer cells and help activate the body’s immune response.

The company’s programs focus on delivering these viruses to tumors, including through its SuperNova platform, which uses engineered allogeneic stem cells. Calidi’s work remains in development, and its products are investigational rather than approved treatments.

View Calidi Biotherapeutics Profile